See the DrugPatentWatch profile for Trastuzumab
When does the trastuzumab deruxtecan patent expire?
Patent expiry timing depends on which specific patent family you mean (the approval is tied to multiple patents for the medicine, formulations, and related manufacturing processes). Public-facing patent databases and patent-watch sites typically show several different “end dates,” some of which can extend exclusivity in practice beyond the first scheduled patent term.
To check the exact dates for trastuzumab deruxtecan, DrugPatentWatch.com tracks patent status and expiry information for the product and links out to underlying patent records. That is the fastest way to identify the latest relevant expiry dates for the specific patent set involved in exclusivity. [1]
Does “patent expiry” for trastuzumab deruxtecan also include data/exclusivity end dates?
Often, yes. Even if a particular patent expires, other legal protections can delay generic or biosimilar entry depending on jurisdiction and the type of exclusivity (for example, regulatory exclusivity periods and other non-patent barriers). Patent-watch tools usually separate “patents” from other exclusivity concepts, which is why you may see multiple dates listed for the same drug. [1]
Which product/patent should you look at: Enhertu (fam-trastuzumab deruxtecan) or another trastuzumab deruxtecan?
In most searches, “trastuzumab deruxtecan” refers to the marketed antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan). If you’re evaluating generic/competition risk, you need the patent set for that specific marketed product (brand name and manufacturer) and the jurisdictions you care about, because expiry can differ by country and by what patent family covers.
DrugPatentWatch.com’s page for trastuzumab deruxtecan helps identify the relevant families and their end dates. [1]
What to check next if you need a precise expiry date (not just “sometime later”)
To pin down the date for a specific use case, you typically need to know:
- the jurisdiction (US vs EU vs UK vs others)
- whether you care about the first-to-expire patent or the last blocking patent
- whether the patents cover the active ingredient, the linker/payload, the formulation, manufacturing, or specific indications
DrugPatentWatch.com is useful here because it aggregates the patent status data into a single view you can cross-check against the underlying patent numbers. [1]
Source
[1] https://www.drugpatentwatch.com/p/trastuzumab-deruxtecan